GleamWall
中文EN

DRUG BRIGHT MINDS BIOSCIENCES INC. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1827401 · Reporting currency CAD · Fiscal year ends 09/30

Financial factors as of 2024-09-30 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY62.0%
TTM EPS YoY67.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.2%
ROA-43.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.3%
Debt / equity0.00x
Current ratio11.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-14.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY2024*2024-09-30FY2023*2023-09-30
Income statement
Revenue——
R&D expense1.18M5.00M
SG&A expense264,009278,809
Income tax00
Net income-2.80M-7.37M
EPS (basic)-0.65-1.98
EPS (diluted)-0.65-1.98
Weighted avg. shares (diluted)4.31M3.72M
Balance sheet
Cash & equivalents5.72M6.75M
Current assets5.99M6.81M
Total assets6.10M6.88M
Current liabilities528,683280,856
Total liabilities568,259280,856
Shareholders' equity5.54M6.60M
Cash flow statement
Operating cash flow-1.85M-7.02M
Financing cash flow810,5722.19M
Depreciation & amortization73,35772,450
Stock-based compensation839,7711.15M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.